Fig. 2From: Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapyThe immunogenicity rates in CoronaVac and in BNT162b2 groups (IS: Immunosuppressive group, HC: Healthy controls)Back to article page